Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(3-4):189-202.
doi: 10.1080/15504263.2015.1100471.

Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study

Tracy L Hellem  1   2 , Young-Hoon Sung  1 , Xian-Feng Shi  1   3 , Marjorie A Pett  2 , Gwen Latendresse  2 , Jubel Morgan  1   3 , Rebekah S Huber  1 , Danielle Kuykendall  1 , Kelly J Lundberg  3 , Perry F Renshaw  1   3   4
Affiliations

Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study

Tracy L Hellem et al. J Dual Diagn. 2015.

Abstract

Objective: Depression among methamphetamine users is more prevalent in females than males, but gender-specific treatment options for this comorbidity have not been described. Reduced brain phosphocreatine levels have been shown to be lower in female methamphetamine users compared to males, and, of relevance, studies have demonstrated an association between treatment-resistant depression and reduced brain phosphocreatine concentrations. The nutritional supplement creatine monohydrate has been reported to reduce symptoms of depression in female adolescents and adults taking antidepressants, as well as to increase brain phosphocreatine in healthy volunteers. Therefore, the purpose of this pilot study was to investigate creatine monohydrate as a treatment for depression in female methamphetamine users.

Methods: Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 g of daily creatine monohydrate and of these 14, 11 females completed the study. Depression was measured using the Hamilton Depression Rating Scale (HAMD) and brain phosphocreatine levels were measured using phosphorus magnetic resonance spectroscopy pre- and post-creatine treatment. Secondary outcome measures included anxiety symptoms, measured with the Beck Anxiety Inventory (BAI), as well as methamphetamine use, monitored by twice weekly urine drug screens and self-reported use.

Results: The results of a linear mixed effects repeated measures model showed significantly reduced HAMD and BAI scores as early as week 2 when compared to baseline scores. This improvement was maintained through study completion. Brain phosphocreatine concentrations were higher at the second phosphorus magnetic resonance spectroscopy scan compared to the baseline scan; Mbaseline = 0.223 (SD = 0.013) vs. Mpost-treatment = 0.233 (SD = 0.009), t (9) = 2.905, p <.01, suggesting that creatine increased phosphocreatine levels. Also, a reduction in methamphetamine positive urine drug screens of greater than 50% was observed by week 6. Finally, creatine was well tolerated and adverse events that were related to gastrointestinal symptoms and muscle cramping were determined as possibly related to creatine.

Conclusions: The current study suggests that creatine treatment may be a promising therapeutic approach for females with depression and comorbid methamphetamine dependence. This study is registered on clinicaltrials.gov (NCT01514630).

Keywords: co-occurring; comorbidity; depression; methamphetamine dependence; neuroimaging; substance use disorders; women's health.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Dr. Perry Renshaw serves as a consultant to Kyowa Hakko, Tal Medical and Ridge Diagnostics. He has received research support from GlaxoSmithKline and Roche. Dr. Perry Renshaw is an inventor on a patent application that has been assigned to the University of Utah, which describes the use of creatine as a treatment for depressive disorders. All other authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Screening, enrollment and study completion data
Figure 2
Figure 2
Change in individual Hamilton Depression Rating Scale scores HAMD = Hamilton Depression Rating Scale Treatment response = score of 8.75 or below
Figure 3
Figure 3
Change in mean Hamilton Depression Rating Scale score HAMD = Hamilton Depression Rating Scale
Figure 4
Figure 4
Individual brain phosphocreatine levels pre and post creatine treatment for completers
Figure 5
Figure 5
Change in individual Beck Anxiety Inventory scores BAI = Beck Anxiety Inventory Treatment response = 9.8
Figure 6
Figure 6
Change in mean Beck Anxiety Inventory scores BAI = Beck Anxiety Inventory
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Medicine. 2008;10(4):275–290. doi: 10.1007/s12017-008-8053-y. - DOI - PMC - PubMed
    1. Allen PJ, D’Anci KE, Kanarek RB, Renshaw PF. Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner. Neuropsychopharmacology. 2010;35(2):534–546. doi: 10.1038/npp.2009.160. - DOI - PMC - PubMed
    1. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Research Bulletin. 2008;76(4):329–343. - PubMed
    1. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? American Journal of Psychiatry. 2004;161:2163–2177. - PubMed
    1. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology. 1988;56(6):893–897. - PubMed

Associated data